Shares of Nektar Therapeutics (NASDAQ:NKTR) have earned a consensus recommendation of “Buy” from the fifteen brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $71.56.
Several analysts have recently commented on the company. ValuEngine cut Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, June 3rd. William Blair restated a “buy” rating on shares of Nektar Therapeutics in a report on Friday, June 14th. Zacks Investment Research cut Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Cowen set a $200.00 target price on Lululemon Athletica and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, BidaskClub upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, June 20th.
In other news, SVP Stephen K. Doberstein sold 3,461 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $31.37, for a total transaction of $108,571.57. Following the completion of the transaction, the senior vice president now directly owns 95,913 shares in the company, valued at approximately $3,008,790.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Gil M. Labrucherie sold 25,000 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $34.57, for a total value of $864,250.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 219,949 shares of company stock valued at $7,285,900. Corporate insiders own 4.02% of the company’s stock.
Shares of NKTR stock traded up $0.19 during trading hours on Friday, hitting $33.72. 991,644 shares of the company’s stock were exchanged, compared to its average volume of 1,285,380. The company has a 50-day moving average price of $34.03. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21. The firm has a market cap of $5.84 billion, a PE ratio of 8.92 and a beta of 2.74. Nektar Therapeutics has a 52 week low of $29.22 and a 52 week high of $69.76.
Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.03. The company had revenue of $28.22 million for the quarter, compared to analysts’ expectations of $25.45 million. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. During the same quarter in the prior year, the business earned ($0.60) earnings per share. As a group, research analysts expect that Nektar Therapeutics will post -3.14 earnings per share for the current year.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Article: How to Use a Moving Average for Trading
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.